Literature DB >> 34258053

Manifestations and Virus Detection in the Ocular Surface of Adult COVID-19 Patients: A Meta-Analysis.

Yu-Yen Chen1,2,3,4, Yung-Feng Yen5,6,7, Li-Ying Huang8,9, Pesus Chou2,3.   

Abstract

PURPOSE: This study aims to examine the prevalence rate of ocular manifestations and the positive rate for the real-time reverse transcriptase-polymerase chain reaction (RT-PCR) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in conjunctival/tear swabs among adult patients with coronavirus disease 2019 (COVID-19).
METHODS: PubMed and EMBASE were reviewed between December 1, 2019, and January 31, 2021, and only peer-reviewed clinical studies in our pooled analyses were included. Details regarding the patient numbers, demographics, ocular manifestations, positivity of ocular surface RT-PCR, and severity of pneumonia were recorded from each study. Primary outcomes were the occurrence of ocular manifestations and virus detection on the ocular surface. Meanwhile, secondary outcomes included frequencies of various ocular symptoms/signs (s/s), the proportion of patients with ocular manifestation as the initial symptom, and the relationship between the severity of pneumonia and the presentation of ocular manifestations.
RESULTS: In total, 35 studies with 4,432 adult COVID-19 patients were included in this analysis. The overall prevalence rate of ocular manifestations was found to be 11.3%, and the positive rate of SARS-CoV-2 in the ocular surface was 7.4%. The four most common ocular s/s were follicular conjunctivitis, redness, watering, and discharge. A proportion of 3.3% presented with ocular s/s preceding other findings. Besides, patients with higher severity of pneumonia were more likely to have ocular manifestations (odds ratio = 2.25; 95% confidence interval (CI): 1.45-3.50).
CONCLUSION: As per our findings, it was determined that ocular transmission of SARS-CoV-2 might be possible, highlighting the importance of eye protective equipment among healthcare personnel.
Copyright © 2021 Yu-Yen Chen et al.

Entities:  

Year:  2021        PMID: 34258053      PMCID: PMC8225454          DOI: 10.1155/2021/9997631

Source DB:  PubMed          Journal:  J Ophthalmol        ISSN: 2090-004X            Impact factor:   1.909


  46 in total

1.  Outcomes of the Ophthalmic Examinations in Patients Infected by SARS-CoV-2.

Authors:  Ali Altan Ertan Boz; Mahmut Atum; Burçin Çakır; Oğuz Karabay; Erkan Çelik; Gürsoy Alagöz
Journal:  Ocul Immunol Inflamm       Date:  2020-11-23       Impact factor: 3.070

2.  Clinical Characteristics of COVID-19 Patients With Gastrointestinal Symptoms in Northern Italy: A Single-Center Cohort Study.

Authors:  Mario Schettino; Lucienne Pellegrini; Desiree Picascia; Simone Saibeni; Cristina Bezzio; Francesco Bini; Barbara F Omazzi; Massimo Devani; Ilaria Arena; Marco Bongiovanni; Gianpiero Manes; Cristina Maria Rita Della Corte
Journal:  Am J Gastroenterol       Date:  2021-02-01       Impact factor: 10.864

3.  SARS-CoV-2 in the ocular surface of COVID-19 patients.

Authors:  Hua-Tao Xie; Shi-Yun Jiang; Kang-Kang Xu; Xin Liu; Bing Xu; Lin Wang; Ming-Chang Zhang
Journal:  Eye Vis (Lond)       Date:  2020-04-26

4.  Conjunctivitis in COVID-19 patients: frequency and clinical presentation.

Authors:  Noemi Güemes-Villahoz; Barbara Burgos-Blasco; Julián García-Feijoó; Federico Sáenz-Francés; Pedro Arriola-Villalobos; Jose María Martinez-de-la-Casa; Jose Manuel Benítez-Del-Castillo; María Herrera de la Muela
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2020-08-29       Impact factor: 3.117

5.  Pathological findings of COVID-19 associated with acute respiratory distress syndrome.

Authors:  Zhe Xu; Lei Shi; Yijin Wang; Jiyuan Zhang; Lei Huang; Chao Zhang; Shuhong Liu; Peng Zhao; Hongxia Liu; Li Zhu; Yanhong Tai; Changqing Bai; Tingting Gao; Jinwen Song; Peng Xia; Jinghui Dong; Jingmin Zhao; Fu-Sheng Wang
Journal:  Lancet Respir Med       Date:  2020-02-18       Impact factor: 30.700

6.  Evaluation of ocular symptoms and tropism of SARS-CoV-2 in patients confirmed with COVID-19.

Authors:  Nan Hong; Wangshu Yu; Jianhua Xia; Ye Shen; Maurice Yap; Wei Han
Journal:  Acta Ophthalmol       Date:  2020-04-26       Impact factor: 3.761

7.  Presence of viral RNA of SARS-CoV-2 in conjunctival swab specimens of COVID-19 patients.

Authors:  Kiran Kumar; Akshata A Prakash; Suresh Babu Gangasagara; Sujatha B L Rathod; K Ravi; Ambica Rangaiah; Sathyanarayan Muthur Shankar; Shantala Gowdara Basawarajappa; Shashi Bhushan; T G Neeraja; Srinivas Khandenahalli; M Swetha; Priyam Gupta; U C Sampritha; Guru N S Prasad; Chakravarthy Raghunathan Jayanthi
Journal:  Indian J Ophthalmol       Date:  2020-06       Impact factor: 1.848

8.  More than loss of taste and smell: burning watering eyes in coronavirus disease 2019.

Authors:  Alexander C Rokohl; Niklas Loreck; Philomena A Wawer Matos; Sarah Zwingelberg; Max Augustin; Felix Dewald; Rafael S Grajewski; Florian Klein; Clara Lehmann; Ludwig M Heindl
Journal:  Clin Microbiol Infect       Date:  2020-08-21       Impact factor: 13.310

9.  Ocular findings in patients with coronavirus disease 2019 (COVID-19) in an outbreak hospital.

Authors:  Hasan Öncül; Fatma Y Öncül; Mehmet F Alakus; Mehtap Çağlayan; Umut Dag
Journal:  J Med Virol       Date:  2020-08-21       Impact factor: 20.693

View more
  2 in total

Review 1.  The mechanism underlying extrapulmonary complications of the coronavirus disease 2019 and its therapeutic implication.

Authors:  Qin Ning; Di Wu; Xiaojing Wang; Dong Xi; Tao Chen; Guang Chen; Hongwu Wang; Huiling Lu; Ming Wang; Lin Zhu; Junjian Hu; Tingting Liu; Ke Ma; Meifang Han; Xiaoping Luo
Journal:  Signal Transduct Target Ther       Date:  2022-02-23

2.  Outpatient human coronavirus associated conjunctivitis in India.

Authors:  N Venkatesh Prajna; Prajna Lalitha; Gonugunta Vishnu Teja; Rameshkumar Gunasekaran; Sankalp S Sharma; Armin Hinterwirth; Kevin Ruder; Lina Zhong; Cindi Chen; Michael Deiner; ChunHong Huang; Benjamin A Pinsky; Thomas M Lietman; Gerami D Seitzman; Thuy Doan
Journal:  J Clin Virol       Date:  2022-09-27       Impact factor: 14.481

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.